[Relationship between epithelial-mesenchymal transition and basal cell-like phenotype in breast cancer]
- PMID: 20021961
[Relationship between epithelial-mesenchymal transition and basal cell-like phenotype in breast cancer]
Abstract
Objectives: To evaluate the relationship between epithelial-mesenchymal transition and basal cell-like phenotype breast cancer (BLBC).
Methods: Three hundred and eighty two cases of breast cancers including basal cell-like, luminal A, luminal B and Her-2 subtypes were collected from 458 cases of invasive breast cancers based on their immunophenotypes. They were then stained immunohistochemically with FOXC-2, vimentin, Syndecan-1 and E-cadherin. The relationship of these markers with the basal cell-like phenotype of breast cancer was studied.
Results: Of the 41 BLBC cases, FOXC-2, vimentin and Syndecan-1 were positive in 14 cases (34.1%), 18 cases (43.9%) and 36 cases (87.7%) respectively; E-cadherin expression was reduced in 26 cases (63.4%). The positive rates of FOXC-2 and vimentin were higher in BLBC than in other subtypes of breast cancer (P < 0.01). The expression of E-cadherin was the lowest among the 4 subtypes of breast cancers (P < 0.01). Syndecan-1 was positive in the stromal cells adjacent to cancer cells in 17 cases (41.5%) BLBC and the expression was higher than that in other subtypes (P = 0.007). There existed a correlation between FOXC-2 and vimentin expression in BLBC (r = 0.607, P < 0.01). The rates of positive lymph nodes in FOXC-2 and vimentin positive BLBC cases were 71.4% and 66.7% respectively, and both were higher than those of FOXC-2 and vimentin negative BLBC cases (P = 0.002 and P = 0.001).
Conclusion: Epithelial-mesenchymal transition is probably related to the basal cell-like phenotype of breast cancers, and this may be one of the reasons accounting for the different biological behavior of BLBC from other subtypes of breast cancer.
Similar articles
-
Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer.J Surg Oncol. 2013 Feb;107(2):188-94. doi: 10.1002/jso.23240. Epub 2012 Aug 8. J Surg Oncol. 2013. PMID: 22886823
-
P-cadherin and vimentin are useful basal markers in breast cancers.Hum Pathol. 2013 Dec;44(12):2782-91. doi: 10.1016/j.humpath.2013.07.029. Epub 2013 Oct 16. Hum Pathol. 2013. PMID: 24139214
-
Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.Hum Pathol. 2013 Nov;44(11):2581-9. doi: 10.1016/j.humpath.2013.07.003. Epub 2013 Sep 20. Hum Pathol. 2013. PMID: 24055090
-
Regulatory mechanisms and clinical significance of vimentin in breast cancer.Biomed Pharmacother. 2021 Jan;133:111068. doi: 10.1016/j.biopha.2020.111068. Epub 2020 Dec 8. Biomed Pharmacother. 2021. PMID: 33378968 Review.
-
Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication.Dis Markers. 2015;2015:796052. doi: 10.1155/2015/796052. Epub 2015 Sep 1. Dis Markers. 2015. PMID: 26420915 Free PMC article. Review.
Cited by
-
E-cadherin expression phenotypes associated with molecular subtypes in invasive non-lobular breast cancer: evidence from a retrospective study and meta-analysis.World J Surg Oncol. 2017 Aug 1;15(1):139. doi: 10.1186/s12957-017-1210-8. World J Surg Oncol. 2017. PMID: 28764784 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous